DanCann Pharma Resultados de beneficios anteriores
Pasado controles de criterios 0/6
DanCann Pharma's earnings have been declining at an average annual rate of -61.8%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 39.2% per year.
Información clave
-61.8%
Tasa de crecimiento de los beneficios
11.6%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 30.5% |
| Tasa de crecimiento de los ingresos | 39.2% |
| Rentabilidad financiera | -931.5% |
| Margen neto | -719.1% |
| Próxima actualización de resultados | 29 Nov 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero DanCann Pharma. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 24 | 8 | -59 | 8 | 0 |
| 31 Mar 24 | 7 | -61 | 8 | 0 |
| 31 Dec 23 | 7 | -62 | 9 | 0 |
| 30 Sep 23 | 7 | -15 | 9 | 0 |
| 30 Jun 23 | 8 | -15 | 9 | 0 |
| 31 Mar 23 | 7 | -16 | 9 | 0 |
| 31 Dec 22 | 7 | -16 | 9 | 0 |
| 30 Sep 22 | 7 | -15 | 8 | 0 |
| 30 Jun 22 | 4 | -15 | 8 | 0 |
| 31 Mar 22 | 4 | -13 | 8 | 0 |
| 31 Dec 21 | 2 | -12 | 7 | 0 |
| 30 Sep 21 | 1 | -9 | 5 | 0 |
| 31 Mar 21 | 0 | -6 | 4 | 0 |
| 31 Dec 20 | 0 | -4 | 3 | 0 |
| 30 Sep 20 | 0 | -2 | 2 | 0 |
| 31 Dec 19 | 0 | 0 | 0 | 0 |
Ingresos de calidad: DANCAN is currently unprofitable.
Margen de beneficios creciente: DANCAN is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: DANCAN is unprofitable, and losses have increased over the past 5 years at a rate of 61.8% per year.
Acelerando crecimiento: Unable to compare DANCAN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: DANCAN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4.5%).
Rentabilidad financiera
Alta ROE: DANCAN has a negative Return on Equity (-931.47%), as it is currently unprofitable.